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The  Staphylococcus  aureus  virulence  factor  clumping  factor  A  (ClfA)  is  a component  of an  investigational
S.  aureus  prophylactic  vaccine.  ClfA enables  S. aureus  to  bind  to ﬁbrinogen  and  platelets  during  the  initial
stages  of  invasive  disease.  Here  we demonstrate  that  ectopic  expression  of  ClfA  is  sufﬁcient  to  render
nonpathogenic  Lactococcus  lactis  lethal  in a murine  model  of  systemic  infection.  In contrast,  L.  lactis
expressing  ClfAY338A,  which  cannot  bind  ﬁbrinogen,  did  not  cause  death  in  the mice.  Pathogenicity  was
also  prevented  by immunization  with  ClfA.  This  model  was  then  used  to deﬁne  a preclinical  correlate  of
protection  by  measuring  functional  antibody  in a S. aureus  ﬁbrinogen  binding  inhibition  assay  (FBI)  and
correlating  that  titer  with  protective  outcomes.  Although  many  humans  have  pre-existing  antibodies  thatibrinogen binding
irulence factor
orrelate of protection
bind to ClfA,  only  sera  with  a threshold  functional  titer  in the  FBI  were  protective  in  this  preclinical  model.
This  conﬁrms  that  ﬁbrinogen  binding  is critical  for ClfA-mediated  pathogenesis  and  demonstrates  that
functional  antibodies  against  ClfA  are  sufﬁcient  to protect  against  ClfA-mediated  pathogenesis  in vivo,
enabling  the  deﬁnition  of a preclinical  correlate  of protection  for ClfA-containing  vaccines  based  on  FBI
titer.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
and sepsis [6–8]. Humans are routinely exposed to S. aureus,  and
develop binding antibodies to ClfA and other surface exposed pro-. Introduction
Staphylococcus aureus is a medically important Gram positive
occus that is carried asymptomatically in the nares of 20–50%
f individuals [1]. S. aureus causes a wide spectrum of disease
anging from relatively mild skin infections, such as impetigo,
o life-threatening bloodstream infections, and is recognized as a
eading cause of serious disease in both community and healthcare-
ssociated settings. In surgical patients in particular, infections are
ssociated with high mortality rates. Survivors of S. aureus surgical
nfections require hospital stays three times longer than uninfected
atients, signiﬁcantly increasing healthcare costs [2]. The burden of
. aureus disease is exacerbated by antibiotic resistance in S. aureus
solates, highlighting the need for an effective prophylactic vaccine.
To establish infection, S. aureus must adhere to host cells, extra-
ellular matrix, or an implanted medical device. S. aureus clumping
∗ Corresponding author. Tel.: +1 845 602 8674; fax: +1 845 602 4350.
E-mail address: Annaliesa.anderson@pﬁzer.com (A.S. Anderson).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.029
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
factor A (ClfA)1 is a member of the microbial surface components
recognizing adhesive matrix molecules (MSCRAMM) family and
plays an important role in establishing wound and foreign body
infections. Originally identiﬁed by Foster and colleagues [3], ClfA
derives its name from its ability to induce clumping of S. aureus
in the presence of ﬁbrinogen. Although S. aureus possesses many
adhesins, ClfA is the major ﬁbrinogen-binding protein in S. aureus
[4,5], binding to the C-terminal end of the ﬁbrinogen -chain. ClfA
is essential during the early stages of infection and its importance
as a S. aureus virulence factor has been demonstrated in several
small animal models of infection, including endocarditis, arthritis,teins, however they generally do not develop functional antibodies
1 Abbreviations: ClfA: Clumping factor A, MSCRAMM:  microbial surface com-
ponent recognizing adhesive matrix molecules, FBI: ﬁbrinogen binding inhibition
assay, rClfA: recombinant ClfA, rmClfA: recombinant ClfA containing a Y338A
mutation.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ine 33
t
T
i
u
a
b
t
i
e
u
a
P
o
ﬁ
I
c
k
t
p
2
2
E
T
p
c
r
v
w
c
m
w
w
e
a
s
a
2
p
k
t
P
t
r
s
l
t
c
B
a
a
L
2
t
a
tI.L. Scully et al. / Vacc
hat can inhibit the binding of the whole bacteria to ﬁbrinogen [9].
his may  be a factor in the failure of passive immunotherapy clin-
cal trials that utilized ClfA enriched antibody preparations from
nvaccinated donors [10]. In contrast, vaccination of small animals
nd humans with a multi-component vaccine that includes recom-
inant ClfA protein was able to induce antibodies that prevented
he binding of S. aureus to ﬁbrinogen using the ﬁbrinogen binding
nhibition (FBI) assay [9].
In this study, we employed the Lactococcus lactis:ClfA ectopic
xpression model [11,12] which showed that ClfA is a critical vir-
lence factor capable of conferring a lethal phenotype upon an
virulent microorganism in a murine systemic infection model.
athogenicity speciﬁcally required ClfA-mediated binding to ﬁbrin-
gen. ClfA antibodies that prevent the binding of S. aureus to
brinogen in vitro abrogated L. lactis:ClfA pathogenicity in vivo.
mmunization with ClfA induced a protective response in mice
hallenged with L. lactis:ClfA. By titrating ClfA immune sera with
nown FBI titer, a threshold protective titer was  deﬁned. This FBI
hreshold protective titer can be used as a preclinical correlate of
rotection for ClfA-containing vaccines.
. Materials and methods
.1. Cloning and expression of recombinant ClfA proteins
Enzymes for DNA manipulation were obtained from New
ngland Biolabs and Takara Bio and primers from Integrated DNA
echnologies. DNA manipulations were performed using standard
rocedures. Synthetic codon optimized DNA sequence (Blue Heron)
orresponding to ClfA amino acids 40–559 (domains N1N2N3,
ClfA) from S. aureus PFESA0043 was subcloned into a pET30a
ector. A ClfA variant lacking ﬁbrinogen-binding activity (rmClfA)
as constructed by DNA synthesis and replacement. Following
onﬁrmation of DNA sequence, the wild type rClfA N1N2N3 frag-
ent and the corresponding rmClfA ﬁbrinogen binding mutant
ere expressed as recombinant proteins in Escherichia coli. Proteins
ere puriﬁed using a combination of hydrophobic and anion-
xchange chromatography [9], quantitated with a bicinchoninic
cid assay (Pierce Biochem), purity assessed by sodium dodecyl
ulfate-polyacrylamide gel electrophoresis, and endotoxin levels
nalyzed using the Limulus amebocyte lysate assay (Charles River).
.2. L. lactis strains
L. lactis cultures were grown in M17  media (Difco). The pKS80
lasmid coding for wild type S. aureus ClfA (pKS80/clfA) was
indly provided by T. Foster and used to generate the L. lac-
is:ClfA strain. Plasmid DNA was isolated from L. lactis via Qiaﬁlter
lasmid maxikit (Qiagen) per manufacturer’s instructions, except
hat cells were grown to late exponential phase, harvested and
esuspended in THMS (30 mM Tris-HCl pH 8, 3 mM MgCl2 in 25%
ucrose) supplemented with 2 mg/mL  lysozyme. A ClfA variant
acking ﬁbrinogen-binding activity was constructed by introducing
he Y338A amino acid substitution by overlap primer polymerase
hain reaction (PCR) using pKS80/clfA as template. A ∼600 bp
pmI/BclI restriction enzyme fragment spanning the Y338A amino
cid substitution was then subcloned into pKS80/clfA. The amino
cid substitution was sequence-veriﬁed, and used to generate the
. lactis:ClfAm strain.
.3. Flow cytometryBacteria were heat-killed by treatment for one hour at 60 oC and
hen blocked with 10% porcine serum/PBS to prevent nonspeciﬁc
ntibody binding. Mouse ClfA monoclonal antibody or isotype con-
rol was added (20 g/mL) and incubated for 30 min  on ice. Cells (2015) 5452–5457 5453
were then sequentially incubated with biotinylated anti-mouse IgG
(Jackson Immunoresearch), streptavidin-PE (BD Biosciences) and
then with a series of washes using 10% porcine serum/PBS. Pel-
lets were resuspended in 1% paraformaldehyde. A total of 20,000
events per well were acquired on a BD LSR II ﬂow cytometer and
analyzed using FlowJo v10 software (Tree Star). The mean ﬂuores-
cence intensity (MFI) of the PE channel was  determined for each
sample after gating on bacterial cells in the logarithmic FSC versus
SSC dot plot. A sample was considered positive if the MFI value was
at least three times the control mouse IgG MFI and greater than
100.
2.4. Fibrinogen binding assay
Human ﬁbrinogen (Fg) (Calbiotech) was immobilized onto
microtiter plates by incubating 100 L/well of 3 g/mL ﬁbrinogen
solution in TBS, pH 7.4 buffer overnight at 4 ◦C, and either 5 M
rClfA or rmClfA were added into the wells. Unbound rClfA or rmClfA
was removed by washing microtiter plates with TBS, pH 7.4 buffer
containing 0.05% Tween 20 (TBS-Tween), and bound rClfA or rmClfA
was detected with polyclonal mouse anti-rClfA antibody, followed
by a secondary detection antibody linked to alkaline phosphatase
(SouthernBiotech). Signal was developed by adding pNPP substrate
(KPL), and absorbance at 405 nm was  read on a Spectramax Plus
spectrophotometer (molecular devices).
2.5. Fibrinogen binding inhibition assay
Fg binding inhibition assays were performed as previously
described [9]. Brieﬂy, microtiter plate wells were coated with
1.7 g/mL human Fg (Calbiochem) and then incubated with block-
ing solution (MBA, GE Healthcare) to reduce nonspeciﬁc binding.
L. lactis isolates (106–107 CFU) were either added directly to the
Fg-coated plate or preincubated with antisera and subsequently
transferred to the Fg coated plate. After 30 min  at 37 oC, wells
were washed to remove non-adherent cells, and adherent cells
were quantiﬁed using the luciferase-based BacTiter-Glo® lysis
reagent (Promega) and read on an Envision 2100 Multilabel Reader
(Perkin Elmer L100) or Spectramax luminometer Model L (Molec-
ular Devices).
2.6. Murine challenge experiments
All animal work was performed in strict accordance with
approved Institutional Animal Care and Use Committee (IACUC)
protocols at an American Association of Laboratory Animal Sci-
ence (AALAS) accredited facility. Female 6–8 week old BALB/c mice
(Charles River Laboratories) were used for active immunization
experiments, and 10–12 week old mice were used for preincu-
bation, passive immunization, and challenge studies. Number of
animals per group is indicated in the legend of each ﬁgure. For active
immunization experiments, mice were immunized subcutaneously
at weeks 0, 3, and 6 with rmClfA + AlPO4, or AlPO4 alone. Mice were
bled on days 0 and 56, and challenged with L. lactis:ClfA on day 60.
For passive immunization experiments, the animals were adminis-
tered 1.5 mg  of the functional anti-ClfA mAb  12–9 or PBS control via
intraperitoneal injection (IP) 16 h prior to bacterial challenge. For
preincubation experiments, ∼1 × 10e9 CFU of L. lactis:ClfA bacteria
were preincubated for two  hours at 4 ◦C with varying amounts of
the 12–9 mAb  (10, 15, 25, 50, or 100 g), 100 g of the ClfA mAb
15EC6 [13], 100 g of control mAb, varying amounts of the mouse
polyclonal ClfA antibody, or PBS. Bacteria were pelleted by centrifu-
gation (4000×g, 4 ◦C, 15 min), the supernatant containing unbound
mAb  was decanted, and the bacterial pellet was resuspended in PBS
for injection. Mice were challenged with ∼1 × 10e9 CFU/mouse of
L.lactis:vector, L.lactis:ClfA, or L.lactis:ClfAm via tail vein injection,
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Fig. 1. Surface expressed ClfA on L. lactis mediates binding to ﬁbrinogen. (A) Flow cytometry. L. lactis:vector, L. lactis:ClfA, L. lactis:ClfAm or clinical S. aureus strains (PFESA0158,
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UFESA0186) were stained to detect the surface expression of ClfA by ﬂow cytometry.
lfA  or rClfAm were evaluated for the ability to bind ﬁbrinogen by ELISA. (C) Fibrin
ere  assessed for their ability to bind to ﬁbrinogen as described in the Materials an
nd survival was monitored for 7 days post challenge. Data were
nalyzed using GraphPad Prism software (GraphPad Software, Inc.).
.7. Murine gross necropsy and tissue histopathology
Three L. lactis:ClfA and two L. lactis:vector control infected mice
ere examined for gross ﬁndings at necropsy. At necropsy, liver,
pleen, lung, gut, kidney, and pancreas were collected and ﬁxed in
0% Neutral Buffered Formalin (NBF). After the tissues were ﬁxed
or 24 h in 10% NBF, they were cassetted individually to maintain
dentity and processed whole on a Sakura VIP 5 series by dehydrat-
ng through a series of graded ethanol solutions, cleared with xylene
nd impregnated with parafﬁn. The tissues were embedded in block
nd sectioned in 4 m thickness. Sectioned tissues were heated in a
0 degree oven for a minimum of 1 h, stained via automated linear
tainer with hematoxylin-eosin (HE) and coverslipped. Slides were
xamined by a trained pathologist and images captured on a EVOS®
L Auto Cell Imaging System (Life Technologies) using EVOS® FL
uto Software Revision 1.6 (Life Technologies).
. Results
.1. ClfA-dependent binding of L. lactis to human ﬁbrinogen
Adhesion to host substrate(s) is an early step in the establish-
ent of an invasive bacterial infection, and S. aureus has multipleedundant mechanisms that enable binding to host factors in vivo.
o experimentally probe the role of ClfA in adhesion in isolation, we
xpressed S. aureus ClfA in the nonpathogenic bacterium L. lactis.
nlike L. lactis bearing only the expression vector (L. lactis:vector),single amino acid substitution in ClfA abrogates binding to ﬁbrinogen. Recombinant
binding of L. lactis strains. L. lactis cells expressing vector alone, ClfA or ClfAY338A
hods.
expression of ClfA is detected on the surface of L. lactis:ClfA by ﬂow
cytometry (Fig. 1A). ClfA expression on two  S. aureus clinical isolates
is shown for comparison. Both recombinant ClfA (rClfA) in isolation
(Fig. 1B) and rClfA expressed on the surface of L. lactis (L. lactis:ClfA,
Fig. 1C) bound to immobilized human ﬁbrinogen.
While ClfA is the primary ﬁbrinogen-binding adhesion factor of
S. aureus, ClfA has also been described to bind Factor I and facilitate
integrin binding, which may  contribute to ClfA-mediated virulence
[4,14,15]. Loughman et al had previously shown that the intro-
duction of two amino acid substitutions into the ClfA A domain
abrogate ﬁbrinogen binding [16]. To ask whether ﬁbrinogen bind-
ing is fully or only partially responsible for ClfA-mediated virulence,
a single point mutation was  introduced into the ﬁbrinogen-binding
A domain of clfA, to generate a Y338A substitution in the gene prod-
uct. The Y338A substitution did not impact ClfA surface expression
as detected by ﬂow cytometry (Fig. 1A), but did abrogate binding to
immobilized ﬁbrinogen, whether coupled to Sepharose on an afﬁn-
ity chromatography column (data not shown), or bound to plastic
on a microtiter plate (Fig. 1B). Likewise, L. lactis strains bearing the
nonrecombinant expression vector (L. lactis:vector) or expressing
the Y338A substitution mutant (L. lactis:ClfAm) were unable to bind
to ﬁbrinogen in vitro (Fig. 1C).
3.2. ClfA-dependent virulence in mice challenged with L.
lactis:ClfAQue et al. [11] have reported that heterologous expres-
sion of S. aureus ClfA enhances L. lactis pathogenicity in a rat
endocarditis model. To better understand ClfA-mediated virulence
in vivo, mice were challenged systemically with L. lactis:ClfA or
I.L. Scully et al. / Vaccine 33 (2015) 5452–5457 5455
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Fig. 2. Heterologous expression of S. aureus ClfA with functional ﬁbrinogen binding
activity is able to confer a lethal phenotype to L. lactis in a mouse model of infection.
(A)  Female BALB/c mice (n—10/group) were challenged IV with ∼1 × 10e9 CFU L.
lactis:ClfA or the L. lactis:vector control strain. Survival was  monitored twice per day
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Table 1
Active vaccination with rmClfA protects against lethal L. lactis:ClfA challenge. Mice
(n—9–10/group per study) were immunized three times (weeks 0, 3 and 6) with
rmClfA + AlPO4 or with AlPO4 alone, and then challenged IV with ∼1.2 × 10e9 CFU
of  L. lactis:ClfA. Survival was  monitored for 7 days. Fisher’s exact test was used to
determine p-values.
Study Vaccine % Survival
at 24 h
p-value versus
control
1 rmClfA + AlPO4 90 <0.0001
Vehicle 0 –
2 rmClfA + AlPO4 80 0.0028
Vehicle 20 –
3 rmClfA + AlPO4 60 0.0006
Vehicle 0 –
for studies that include multiple animals.
Instead preincubation of the L. lactis:ClfA bacteria with func-
tional ClfA antibody concentrations with a range of FBI titers
0 24 48 72 96 120
0
20
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100
1.5mg 12-9
1.5mg 15EC6
1.5mg IgG1
PBS
hours
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a
lor  7 days. (B) Female BALB/c mice (n 10/group) were challenged IV with ∼1 × 10e9
FU L. lactis:ClfA, L. lactis:ClfAm, or the L. lactis:vector strains. Survival was monitored
wice per day for 7 days.
he L. lactis:vector control, and survival was monitored. While
here was no detectable virulence in mice challenged with the L.
actis:vector organisms, the L. lactis:ClfA organisms were highly vir-
lent, with most animals succumbing to the infection within 24 h
Fig. 2). Necroscopies with tissue histopathology were conducted
fter challenge which demonstrated systemic bacteremia in the
ice challenged with the ClfA expressing L. lactis strain, but not
n mice challenged with L. lactis alone (Supplemental Fig. 1).
Virulence of the L. lactis:ClfAm strain was then compared to
he wild type L.lactis:ClfA strain in the mouse systemic infection
odel. Female BALB/c mice were challenged IV with ∼1 × 10e9
FU of L. lactis:vector, L. lactis:ClfA, or L. lactis:ClfAm. Strikingly, the
ingle Y338A substitution in ClfA rendered the L. lactis:ClfAm avir-
lent (Fig. 2B). This result suggests that ClfA-mediated virulence in
his model is solely dependent upon functional ﬁbrinogen binding
ctivity.
.3. Active vaccination with rmClfA and passive immunization
ith a functional ClfA monoclonal antibody can ameliorate
lfA-mediated virulence
Mice were immunized with rmClfA + AlPO4 or AlPO4 alone
o determine if vaccination could protect against ClfA-mediated
athogenesis in the L. lactis:ClfA systemic infection model. While
he majority of animals vaccinated with vehicle succumbed to
nfection within 24 h, 76% of ClfA-immunized mice survived the
hallenge (Table 1), suggesting that a vaccine-induced immune
esponse can protect against ClfA-mediated pathogenesis.
To further interrogate ClfA-mediated pathogenesis in the L. lac-
is:ClfA systemic infection model, passive immunization studies
ere conducted using two ClfA mAbs (12–9 and 15EC6). Although
oth mAbs bind ClfA, 12–9 is capable of interrupting the bind-
ng of S. aureus to ﬁbrinogen, as measured by the FBI assay, whileMeta-analysis rmClfA + AlPO4 76 <0.0001
Vehicle 7 –
15EC6 cannot [9]. Likewise, passive administration of the functional
(i.e., able to inhibit ClfA ﬁbrinogen-binding activity) ClfA mAb  12–9
completely protected mice challenged with L. lactis:ClfA, while the
nonfunctional mAb  15EC6 did not protect (Fig. 3). Together, these
results demonstrate that the lethal phenotype of L. lactis:ClfA is
dependent upon the ability of ClfA to bind ﬁbrinogen. Disruption
of that interaction, either genetically via the Y338A substitution
or with the 12–9 mAb  that blocks S. aureus binding to ﬁbrinogen,
abrogates the lethal phenotype.
3.4. Deﬁning the preclinical correlate of protection for
ClfA-containing vaccines
Using the FBI assay in conjunction with the ClfA-dependent
mouse model of infection, we  sought to identify a threshold
anti-ClfA antibody titer that correlates with protection from the
lethal L. lactis:ClfA challenge. Those animals that were immunized
with rmClfA and survived challenge with L. lactis:ClfA all had
high FBI titers (Geometric mean titer (GMT)——1214). Both the
AlPO4-treated control animals and the rmClfA-vaccinated animals
that did not survive bacterial challenge had undetectable FBI
titers (data not shown). Due to the large disparity in FBI titer,
active immunization cannot provide sufﬁcient accuracy to deﬁne
a protective anti-ClfA threshold. While passive immunization
permits a better controlled titration of antibody and an alternative
experimental approach to deﬁne a protective titer, infusion of
anti-ClfA antibody into the animal prior to bacterial challenge
requires large amounts of antibody, and is therefore less practicalFig. 3. Passive immunization with the functional anti-ClfA mAb  12–9 is protective
against lethal L. lactis:ClfA challenge in mice. Mice (n—10–11/group) were passively
immunized with 1.5 mg 12–9, 15EC6, an IgG isotype control mAb or PBS, and then
challenged IV with ∼1.2 × 10e9 CFU of L. lactis:ClfA. Survival was  monitored for 7
days.
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Fig. 4. Preopsonization of L. lactis:ClfA with a functional monoclonal antibody is
protective in a murine model of sepsis. (A) Approximately 1 × 10e9 CFU of L. lac-
tis:ClfA were incubated with 100 g of mAb  or with PBS for 2 h. After removing
unbound mAb, the bacteria were resuspended in PBS before being injected IV into
female BALB/c mice (n—8–10/group). Survival was monitored 2X/day for 7 days.
(B)  Approximately 1 × 10e9 CFU of L. lactis:ClfA were incubated with the indicated
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mmount of mAb  or PBS for 2 h. After removing unbound mAb, the bacteria were resus-
ended in PBS before being injected IV into female BALB/c mice (n—9–11/group).
urvival was monitored 2X/day for 7 days.
as chosen as an experimental strategy to identify a protective
hreshold. In an initial study designed to validate the approach,
ice that were challenged with L. lactis:ClfA preincubated with
00 g of the functional 12–9 mAb  were able to survive the bac-
erial challenge (Fig. 4A). In contrast, mice challenged with L.
actis:ClfA preincubated with 100 g of either an isotype control
Ab  or the non-functional 15EC6 mAb  were highly susceptible.
here was a dose-dependent relationship between survival of mice
n the model and the amount of 12–9 mAb  used to precoat the
. lactis:ClfA. At levels >50 g, preincubation with the 12–9 mAb
as able to completely protect against ClfA-mediated virulence
Fig. 4B). Collectively, this conﬁrmed the passive immunization
ata and enabled us to perform further studies using the prein-
ubation model.
Next we performed serial dilutions of mouse polyclonal ClfA
ntisera to identify the FBI titer required to confer protection from
hallenge with precoated L. lactis:ClfA. Preincubation with mouse
olyclonal sera with a calculated FBI titer of ≥142 was protec-
ive in this model (Table 2). None of the mice challenged with
able 2
dentiﬁcation of a protective FBI threshold with mouse polyclonal anti-ClfA sera.
ooled serum samples from immunized mice were assayed to measure the ﬁbrin-
gen binding inhibition (FBI) titer. Dilutions of pooled immune or nonimmune
ontrol sera were used to preopsonize L. lactis:ClfA before injection into BALB/c
ice (5/group). The number of mice surviving after 7 days is noted.
Group Calculated FBI titer Surviving animals/Total
80% ClfA mouse serum 284 4/4
60% ClfA mouse serum 213 5/5
40% ClfA mouse serum 142 5/5
20% ClfA mouse serum 71 0/4
80% Normal Mouse Serum 40 0/5
50 mcg  12–9 5/5 (2015) 5452–5457
L. lactis:ClfA preincubated with polyclonal anti-ClfA serum with
calculated FBI titers of ≤71 survived the infection. In this model,
an FBI titer of 142 represents the threshold that correlates with
protection.
4. Discussion
The work presented here clearly reafﬁrms ClfA as an impor-
tant S. aureus virulence factor. Ectopic expression of ClfA confers
a lethal phenotype to the innocuous organism L. lactis. ClfA is a
primary ﬁbrinogen-binding factor of S. aureus,  and the ﬁbrinogen-
binding potential of ClfA has been proposed to be critical for its
function [4,17,18]. This is supported by the fact that mice lacking
the ClfA binding site in the ﬁbrinogen  chain are more resistant to
S. aureus sepsis, and S. aureus expressing ClfAPY, which cannot bind
ﬁbrinogen, is far less pathogenic in a murine septic arthritis model
[18]. We  have conﬁrmed that the ﬁbrinogen-binding activity of ClfA
is critical for virulence by using ClfA with a single Y338A amino
acid substitution in the ﬁbrinogen binding domain. ClfAY338A was
unable to bind to ﬁbrinogen, and also was unable to confer the
lethal phenotype when expressed in L. lactis and used to challenge
mice. This ﬁnding clearly demonstrates that the ﬁbrinogen-binding
capacity of ClfA is the primary mechanism of ClfA-mediated patho-
genesis in this model of systemic bacterial infection.
S. aureus causes devastating disease, especially in surgical
populations and in individuals immunocompromized by obesity,
diabetes, or smoking [19–21]. S. aureus disease burden and mor-
tality is compounded by the antibiotic resistant clones, such as
methicillin-resistant USA300. The prevalence of S. aureus disease
and the emergence of antibiotic-resistant S. aureus highlight the
need for an effective S. aureus vaccine. Therefore, we  were inter-
ested to determine if antibodies directed against ClfA could confer
protection. Preincubation with either a functional ClfA monoclonal
antibody or murine polyclonal sera was  sufﬁcient to protect in the
L. lactis:ClfA systemic infection model. This implies that antibod-
ies can abrogate the ClfA-mediated virulence that is dependent
upon ClfA ﬁbrinogen binding. Importantly, only polyclonal serum
which contained functional antibodies, as measured by the ability
to inhibit ﬁbrinogen binding in the FBI assay, could protect in the
preincubation systemic infection model. Despite routine environ-
mental exposure to S. aureus,  humans generally do not appear to
have circulating functional anti-ClfA antibodies that inhibit binding
of whole ClfA-expressing bacteria to ﬁbrinogen [9]. Not surpris-
ingly, therefore, while many human subjects have ClfA binding
antibodies, and some individuals have antibodies that prevent the
binding of ClfA protein to ﬁbrinogen, most human subjects have
functional ClfA antibody titers below the limit of detection in the FBI
assay [9,22]. Similarly, unimmunized mice do not have detectable
FBI titers, and preincubation of L. lactis:ClfA bacteria using serum
samples with FBI titers <142 does not protect in the systemic chal-
lenge model.
The fact that natural exposure does not generally induce func-
tional anti-ClfA antibodies in humans begged the question as to
whether vaccination would be able to induce a protective anti-
ClfA immune response. Hawkins et al had previously shown that
immunization of humans with a ClfA-containing vaccine elicited a
functional response against ClfA [9]. We  immunized mice with ClfA
and showed that active vaccination was capable of protecting mice
in the L. lactis:ClfA systemic infection model. Thus, vaccination may
overcome the inability of natural exposure to induce a functional
anti-ClfA immune response, and this response can be measured by
the FBI assay. These results support the use of the FBI assay as a
preclinical measure of protection and suggest that the assay may
be useful in deﬁning a clinical correlate for protection based on
functional ClfA antibodies for ClfA-containing vaccines.
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Antibodies to ClfA have been tested as a stand-alone therapy in
reclinical models and, while there was some indication of ame-
ioration of S. aureus disease, ultimately these approaches have yet
o be validated in the clinic. It should be noted that one of those
pproaches, Veronate, consisted of puriﬁed total IgG from humans
ith high ClfA binding antibody titers resulting from natural expo-
ure. As natural exposure does not generally induce functional
nti-ClfA antibodies in humans, it is possible that this product
acked efﬁcacy due to the absence of sufﬁcient amounts of func-
ional antibody.
Active vaccination, unlike passive immunotherapy, can induce
he production of functional antibodies to meet the demand posed
y an infection. Prophylactic vaccination has the ability to target
he relatively small inocula of bacteria that initiate an infection,
ather than trying to overcome a fulminant infection. Therefore a
rophylactic vaccine against S. aureus,  especially one containing
ultiple antigens, has a greater likelihood of success than a
assive immunotherapeutic approach. Passive immunotherapies
omposed of well-deﬁned functional antibodies directed against
ell-understood targets remain valuable to ameliorate disease
n emergent situations where there is no time to induce a pro-
ective immune response through vaccination. Here we have
hown that active vaccination can protect against ClfA-mediated
irulence in the L. lactis:ClfA systemic infection model, and that
rotection correlated with the induction of a functional antibody
esponse, as measured by the FBI assay. This work is a signiﬁcant
dvance towards potentially identifying a correlate of protection
or ClfA that could be evaluated in clinical efﬁcacy trials with
lfA-containing vaccines.
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